Local
Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: The Hazard Herald

Extended Phase 3 INDIGO follow-up results, including data from patients who crossed over to VORANIGO® (vorasidenib) from placebo, were presented as an oral presentation on November 14Exploratory INDIGO analysis providing insight into VORANIGO's impact on seizure control and quality of…
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at The Hazard Herald



